Educational Objectives
The Open Session of Society for Urologic Oncology at the AUA annual meeting is intended for urologists, radiation oncologists and medical oncologists who are interested in expanding their knowledge base in the field of urologic oncology. The agenda of this year’s meeting has been shaped by the release of data from three pivotal Phase III trials in prostate cancer over the past year, with an overall theme focusing on approaches to delay tumor progression. A session on Chemoprevention of prostate cancer will focus around the recent results of the Prostate Cancer Prevention Trial (PCPT) using finasteride. A second session will discuss the pros and cons of early hormone therapy in non-metastatic prostate cancer in light of the recent data from the Early Prostate Cancer (EPC) trial of Casodex monotherapy. In addition to the annual Willet Whitmore Lecture, there will be a session focusing on Advances in Advanced Disease. This session will focus on recent advances in the management of hormone refractory disease, including recent results from Phase III trials of docetaxel and promising new targeted agents in late stage development. This will highlight some of the promising biologic agents in development and include discussion of challenges that confront drug development and clinical trial design in oncology. Sessions will include panel discussions and didactic lectures to best update the audience on emerging information and themes.

Strategies to Delay Tumor Progression

1:00 p.m. - 1:15 p.m.
Welcome and Introduction
Ian Thompson, MD
Presentation of SUO Young Investigator Awards – Ian Thompson, MD
Presentation of CapCure Awards – Stuart S. Holden MD
Program Overview –
Martin Gleave MD

2:30 p.m. - 3:00 p.m.
Willet F. Whitmore, Jr. Lecture
Introduction: Ian Thompson, MD
"Urologic Cancer and its Surgeon-Scientists: A Triumphant Past, but What Will be Its Future?"
Lecturer: Paul Lange, MD

1:20 p.m. - 2:00 p.m.
Chemoprevention
1:20 p.m.
Moderator: Gerald L. Andriole Jr., MD –
Review of Active Trials
1:27 p.m.
PCPT Trial – Ian Thompson, MD
1:37 p.m.
View from Europe – Michael Marberger, MD
1:44 p.m.
View from US – Eric A. Klein, MD
1:51 p.m.
Panel Discussion –
(Andriole, Thompson, Marberger, Klein, Fleshner)

3:00 p.m. - 4:00 p.m.
Advances in Advanced Disease
Moderator: Eric Small
Chemotherapy in HRPC – State-of-the-art –
Dan Petrylak
ETA Receptor Antagonist (Atrasentan):
Current Status – Joel Nelson, MD
High Dose Cetuximab + Taxotere in HRPC –
Tomasz Beer, MD
Genasense (Bcl-2 antisense) + Taxotere in
HRPC – Tony Tolcher
Panel Discussion –
(Nelson, Chi, Tolcher, Beer, Petrylak)

3:30 p.m.
Advances in Advanced Disease
Moderator: Eric Small
Chemotherapy in HRPC – State-of-the-art –
Dan Petrylak
ETA Receptor Antagonist (Atrasentan):
Current Status – Joel Nelson, MD
High Dose Cetuximab + Taxotere in HRPC –
Tomasz Beer, MD
Genasense (Bcl-2 antisense) + Taxotere in
HRPC – Tony Tolcher
Panel Discussion –
(Nelson, Chi, Tolcher, Beer, Petrylak)

2:00 p.m. - 2:30 p.m.
Optimal Timing of Early Hormone Therapy
2:00 p.m.
Moderator: Edward M. Messing, MD
2:05 p.m.
PC Trial Results – Peter Iversen
2:15 p.m.
Panel Discussion –
(Messing, Iversen, Jan Adolfsson, Fradel, Klein)

4:00 p.m.
Adjourn

Sponsored by the American Urological Association

Accreditation Statement:
The American Urological Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American Urological Association takes responsibility for the content, quality, and scientific integrity of this CME activity. This CME activity was planned and produced in accordance with the ACCME Essential Areas and Policies.

Credit Hours Designation Statement:
The American Urological Association designates this educational activity for a maximum of 4.0 hours category 1 credit toward the AMA Physician's Recognition Award. Each participant should claim only those hours of credit that he/she actually spent in the educational activity.

AUA Policy on Disclosure:
As a sponsor accredited by the ACCME, the American Urological Association must Insure balance, independence, objectivity and scientific rigor in all its sponsored activities. All faculty participating in a CME accredited sponsored program are expected to disclose to the audience any significant financial interest or other relationships with commercial supporters. The intent of this disclosure is not to prevent a speaker with a significant financial or other relationship from making a presentation, but rather to provide listeners with information on which they can make their own judgments. It remains for the audience to determine of the speaker’s interests or relationships may influence the presentation with regard to exposition or conclusion. When unlisted uses are discussed, these are also indicated.

The opinions and recommendations expressed by faculty/authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the American Urological Association.

Unlabeled or Unapproved Use of Drugs or Devices:
In accordance with the Essential Areas and Policies relating to commercial support, the audience is advised that one or more presentations in this continuing medical education activity may contain reference/s to unlabeled or unapproved uses or drugs or devices.